2de Kraker AT,Kenemans P,Smolders RG,et al. The effects of 17 beta- oestradiol plus dydrogesterone compared with conjugated equine oestro- gens plusmedroxyprogesterone acetate on lipids,apolipoproteins and lipoprotein ( a ) [J]. Maturitas, 2004,49 ( 3 ) : 253 -263.
3Kennedy S, Bergqvist A, Chapron C, et al. ESHRE guideline for the diag- nosis and treatment of endometriosis[J]. Hum Reprod, 2005,20 (10): 2698-2704.
4Tahara M, Matsuoka T, Yokoi T, et al. Treatment of endometriosis with a decreasing dosage of a gonadotropin-releasing hormone agonist (nafare- lin) :a pilot study with low-dose agonist therapy ("draw-back" therapy) [J]. Fertil Steril, 2000,73 : 799-804.
5Kitawaki J, Ishihara H, Kiyomizu M, et al. Maintenance therapy involving a tapering dose of danazol or mid/low doses of oral contraceptive after go- nadotropin-releasing hormone agonist treatment for endometriosis associ- ated pelvic pain[J]. Fertil Steril, 2008,89 (6) : 1831-1835.
6Razic S,Luisi S,Calonaci F,et al. Efficacy of vaginal danazol treatment in women with recurrent deeply infhrating endometriosis[J]. Fertil Steril, 2007,88 (4) :789-794.
7Huang F ,Wang H ,Zou Y ,et al. Effect of GnRH- I1 on the ESC prolifera- tion,apoptosis and VEGF secretion in patients with endometriosis in vitro[J]. Int J Clin Exp Pathol, 2013,6 ( 11 ) : 2487-2496.
8Fedele L, BianChi S,Zanconato G, et al. Use of a levonorgestrel-releasing in trauterine devise in the treatment of rectovaginal endometriosis [J]. Fertil Steril, 2001,75 ( 3 ) : 485 -488.
9Ferreira RA,Vieira CS,Rosa-E-Silva JC,et al. Effects of the levonor- gestrel-releasing intrauterine system on cardiovascular risk markers in pa- tients with endometriosis:a comparative study with he GnRH analogue [J]. Contraception ,2010,81 (2) : 117-122.
